Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
NE.DE.F. Study: Nepafenac/Dexamethasone FDC vs Monotherapies After Cataract Surgery
2025-523367-38-00Phase 3Authorised
- Sponsor
- Medivis
- Start
- Feb 2026
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, single-blind trial in Postoperative ocular inflammation, Conjunctival Erythema and Ocular pain is not a disease; it is a symptom. The canonical disease entity most closely related to persistent, unexplained ocular pain is "ocular neuropathic pain" or "neuropathic ocular pain" comparing Nepafenac + dexamethasone fixed-dose combination, Nepafenac monotherapy and Dexamethasone monotherapy (3 arms). Primary endpoint: Time to resolution of postoperative anterior chamber inflammation. Planned start Feb 2026; status: authorised.
02
Drugs
nepafenacdexamethasone
03
Conditions
Postoperative ocular inflammationConjunctival ErythemaOcular pain is not a disease; it is a symptom. The canonical disease entity most closely related to persistent, unexplained ocular pain is "ocular neuropathic pain" or "neuropathic ocular pain".
Beyond the preview
Go deeper on 2025-523367-38-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2025-523367-38-00.